期刊文献+

Assessment of tumor response to chemotherapy in patients with breast cancer using ^(18)F-FLT: a meta-analysis

Assessment of tumor response to chemotherapy in patients with breast cancer using ^(18)F-FLT: a meta-analysis
下载PDF
导出
摘要 Purpose: To determine the diagnostic performance of 3'-deoxy-3'-18F-fluorothymidine positron emission tomography/computed tomography(FLT PET/CT) and FLT PET for evaluating response to chemotherapy in patients with breast cancer.Methods: Databases such as Pub Med(MEDLINE included) and excerpta medica database(EMBASE), were searched for relevant original articles. The included studies were assessed for methodological quality with quality assessment of diagnosis accuracy studies(QUADAS) score tool. Histopathological analysis and/or clinical and/or radiological follow-up for at least 6 months were used as the reference standard. The data were extracted by two reviewers independently to analyze the sensitivity, specificity, summary receiver operating characteristic(SROC) curve, area under the curve(AUC), and heterogeneity.Results: The present study analyzed a total of 4 selected articles. The pool sensitivity was 0.773 [95% confidence interval(CI): 0.594-0.900]. The pooled specificity was 0.685(95% CI: 0.479-0.849) on basis of FEM. The pooled LR^+, LR^-, and DOR were 2.874(1.492-5.538), 0.293(0.146-0.589), and 14.891(3.238-68.475), respectively. The AUC was 0.8636(±0.0655), and the Q* index was 0.7942(±0.0636).Conclusions: Our results indicate that 18^F-FLT PET/CT or PET is useful to predict chemotherapy response in breast cancer with reasonable sensitivity, specificity and DOR. However, future larger scale clinical trials will be needed to assess the regimen of 18^F-FLT PET/CT or PET in monitoring the response to chemotherapy in breast cancer patients. Purpose: To determine the diagnostic performance of 3'-deoxy-3'-18F-fluorothymidine positron emission tomography/computed tomography(FLT PET/CT) and FLT PET for evaluating response to chemotherapy in patients with breast cancer.Methods: Databases such as Pub Med(MEDLINE included) and excerpta medica database(EMBASE), were searched for relevant original articles. The included studies were assessed for methodological quality with quality assessment of diagnosis accuracy studies(QUADAS) score tool. Histopathological analysis and/or clinical and/or radiological follow-up for at least 6 months were used as the reference standard. The data were extracted by two reviewers independently to analyze the sensitivity, specificity, summary receiver operating characteristic(SROC) curve, area under the curve(AUC), and heterogeneity.Results: The present study analyzed a total of 4 selected articles. The pool sensitivity was 0.773 [95% confidence interval(CI): 0.594-0.900]. The pooled specificity was 0.685(95% CI: 0.479-0.849) on basis of FEM. The pooled LR^+, LR^-, and DOR were 2.874(1.492-5.538), 0.293(0.146-0.589), and 14.891(3.238-68.475), respectively. The AUC was 0.8636(±0.0655), and the Q* index was 0.7942(±0.0636).Conclusions: Our results indicate that 18^F-FLT PET/CT or PET is useful to predict chemotherapy response in breast cancer with reasonable sensitivity, specificity and DOR. However, future larger scale clinical trials will be needed to assess the regimen of 18^F-FLT PET/CT or PET in monitoring the response to chemotherapy in breast cancer patients.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2014年第5期517-524,共8页 中国癌症研究(英文版)
基金 supported by the Open Program of Key Laboratory of Nuclear Medicine, Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine (KF201305 and KF201306) Science and Technology Development Program of Suzhou (SYSD2013076)
关键词 Breast cancer 18 ^F-FLT PET CHEMOTHERAPY META-ANALYSIS Breast cancer 18 ^F-FLT PET chemotherapy meta-analysis
  • 相关文献

参考文献19

  • 1Jemal A,Bray F,Center MM,et al.Global cancer statistics.CA Cancer J Clin 2011;61:69-90.
  • 2Cardoso F,Harbeck N,Fallowfield L,et al.Locally recurrent or metastatic breast cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and followup.Ann Oncol2012;23 Suppl 7:vii11-9.
  • 3RaseyJS,GriersonJR,Wiens LW,et al.Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.J Nucl Med 2002;43:1210-7.
  • 4Whiting P,Rutjes AW,Reitsma JB,et al.The development of QUADAS:a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.BMC Med Res Methodol2003;3:25.
  • 5Whiting PF,Weswood ME,Rutjes AW,et al.Evaluation of QUADAS,a tool for the quality assessment of diagnostic accuracy studies.BMC Med Res Methodol2006;6:9.
  • 6Higgins JP,Thompson SG,Deeks JJ,et al.Measuring inconsistency in meta-analyses.BMJ 2003;327:557-60.
  • 7Zamora J,Abraira V,Muriel A,et al.Meta-DiSc:a software for meta-analysis of test accuracy data.BMC Med Res Methodol 2006;6:31.
  • 8Pio BS,Park CK,Pietras R,et al.Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.Mol Imaging Biol 2006;8:36-42.
  • 9Kenny L,Coombes RC,Vigushin DM,et al.Imaging early changes in proliferation at 1 week post chemotherapy:a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.Eur J Nucl Med Mol Imaging 2007;34:1339-47.
  • 10Kenny LM,Contractor KB,StebbingJ,et al.Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.Clin Cancer Res 2009;15:6649-57.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部